One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Diagnostics ➤ Preimplantation Genetic Testing Market
Preimplantation Genetic Testing Market
Preimplantation Genetic Testing Market
Published date: July 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Diagnostics ➤ Preimplantation Genetic Testing Market

Global Preimplantation Genetic Testing Market By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis) By Product Type(Reagents and Consumables, Instruments, Software);By Technology(Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Other Technologies)By Application(Chromosomal Abnormalities, Aneuploidy Screening, X-linked Diseases, Other Applications)By End-User(Hospitals, Fertility Centers, Diagnostic Centers,and other) By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2033

  • Published date: July 2024
  • Report ID: 12405
  • Number of Pages: 206
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Market Overview
    • Key Takeaways
    • By Procedure Type
    • By Product Type
    • By Technology
    • By Application
    • By End-User
    • Key Market Segments
    • Drivers
    • Trend
    • Restraint
    • Opportunity
    • Regional Analysis
    • Key Player Analysis
    • Recent Developments
    • Report Scope

    Market Overview

    The Global Preimplantation Genetic Testing Market size is expected to be worth around USD 1648.6 Million by 2033 from USD 756.6 Million in 2023, growing at a CAGR of 8.1% during the forecast period from 2024 to 2033.

    Preimplantation genetic testing, also referred to as preimplantation genetic diagnosis, involves screening embryos produced through in vitro fertilization for genetic abnormalities prior to being implanted into uteruses. Medical professionals perform this screening test so as to detect genetic flaws within embryos so as to implant only healthy ones into gestationsal sacs – with its primary goal being increasing likelihood of successful pregnancy while decreasing risks passed from parentage through inheritance of genetic conditions and passing them down through offspring.

    Preimplantation involves different procedures including egg harvesting from either mother or donor eggs then followed by in vitre fertilization followed by in vitreation before final implantation occurs resulting in vitro fertilization followed by in vitreation with final resultant embryo resulting from fertilization followed by in vitre fertilization of resultant embryos during in utero.

    Post-fertilization, eggs are subject to screening to detect genetic abnormalities. Viable embryos may be preserved through freezing while nonviable ones must be discarded; implanting healthy embryos is paramount in order to achieve successful pregnancy; preimplantation genetic testing also offers gender selection but this presents ethical concerns; nonetheless many individuals dealing with sexually linked genetic conditions, single gene donors with chromosomal problems seeking pregnancy as well as older women and those experiencing repeated abortions increasingly seek this therapeutic option for infertility issues are turning towards preimplantation genetic testing as a treatment option as an aid against infertility.

    Preimplantation Genetic Testing Market Size

    Key Takeaways

    • Market Size & Growth: Preimplantation Genetic Testing Market size is expected to be worth around USD 1648.6 Million by 2033 from USD 756.6 Million in 2023, growing at a CAGR of 8.1%.
    • By Procedure Type: In 2023, Preimplantation Genetic Diagnosis held approximately 78% of market revenue share.
    • By Product Type: In 2023, reagent & consumables represented 50.6% of revenue share.
    • By Technology: Polymerase chain reaction (PCR) held the highest revenue share at 40.6% in 2023
    • By Application: Aneuploidy screening dominated the preimplantation genetic testing market in 2023, accounting for 26.8% of its revenue share
    • By End-User: The hospital segment accounted for the highest revenue share of around 40% in 2023
    • Regional Analysis: North America secured 36.4% market share and contributed USD 275.4 Million revenue in 2023.

    By Procedure Type

    In 2023, Preimplantation Genetic Diagnosis held approximately 78% of market revenue share and projected to experience the fastest compound annual growth rate during its forecast period. This segment’s growth can be attributed to increasing awareness among healthcare professionals and consumers regarding genetic testing for specific gene mutations.

    This segment’s growth has been propelled by an increased incidence of single gene diseases and translocation cases, coupled with market entities’ effective implementation of Next-Generation Sequencing (NGS) technology. Preimplantation Genetic Diagnosis (PGD) services play an essential role in screening embryos to detect specific gene mutations that contribute to decreased instances of genetic diseases in newborns.

    Preimplantation Genetic Screening (PGS) services involve screening embryos for any chromosomal abnormalities. PGS screening services are recommended for couples of advanced reproductive age, multiple In Vitro Fertilization (IVF) cycles and repeated miscarriages, or those experiencing repeated pregnancy loss. Due to continually rising demand and advancements in IVF procedures, PGS services look set for lucrative growth in the forecast period. Furthermore, high capacity laboratories that conduct many IVF processes ensure superior PGS services further fueling this growth segment’s expansion.

    By Product Type

    In 2023, reagent & consumables represented 50.6% of revenue and were projected to experience the fastest compound annual growth rate through 2033. PGT’s rising adoption in In Vitro Fertilization (IVF) processes has driven its escalation, leading to over 2.7 million cycles per year and over 500,000 deliveries via IVF yearly – propelling demand for PGT-related consumables such as next-generation sequencing tests such as polymerase chain reaction or fluorescent in-situ hybridization which will continue its upward trajectory in growth over time.

    Instruments held a second-largest share in the preimplantation genetic testing market in 2023, as market players continue to focus on developing advanced genetic testing instruments with accurate results. Furthermore, more hospitals and clinics offering IVF services is projected to drive demand for on-site preimplantation genetic testing of pregnancies requiring PGT services.

    By Technology

    Polymerase chain reaction (PCR) held the highest revenue share at 40.6% in 2023. This is attributable to its wide penetration, cost-effectiveness, and precision; all factors which contributed to its dominant market presence. PCR tests can generate multiple copies of specific genomic segments which increases chances of detecting chromosomal abnormalities within samples; furthermore its specificity and sensitivity make PCR an excellent method for various genetic diagnoses.

    Next-Generation Sequencing (NGS) is projected to experience the fastest compound annual growth rate during its forecast period, thanks to its superior accuracy compared with other tests and ability to sequence large amounts of DNA rapidly. Technological advances have expanded NGS’ scope, enabling detection of additional chromosomal abnormalities.

    By Application

    Aneuploidy screening dominated the preimplantation genetic testing market in 2023, accounting for 26.8% of its revenue share, and is anticipated to show an unprecedented compound annual growth rate throughout its forecast period. Aneuploidy screening techniques are commonly used to evaluate embryo quality during In Vitro Fertilization (IVF). Their projected expansion can be attributed to the rising adoption of such techniques and innovative products entering the market.

    HLA Typing was the second-highest market share holder in 2023. This was driven by preimplantation genetic testing, specifically embryo HLA typing for stem cell therapy; HLA typing provides crucial preimplantation genetic tests with higher survival rates compared to transplantation from unrelated donors; thus amplifying HLA testing’s importance in preimplantation genetic testing.

    By End-User

    The hospital segment accounted for the highest revenue share of around 40% in 2023. High patient inflow, improved healthcare infrastructure, and the presence of public and private hospitals offering IVF services are some of the major factors driving the segment’s growth. Mostly, couples who are seeking fertility treatment go to hospitals for further treatments, because of the highly advanced technology available at hospitals. In addition, the rise in research at hospitals is expected to increase testing rates in hospital settings. Moreover, the hospital segment is projected to experience the fastest growth in the coming years.

    The fertility centers segment held the second-largest share of the preimplantation genetic testing industry in 2023. Improvement of healthcare infrastructure in fertility centers and technological advancements in testing services are expected to drive the growth of the segment in the forthcoming years.

    Preimplantation Genetic Testing Market Share

    Key Market Segments

    Procedure Type

    • Preimplantation Genetic Screening
    • Preimplantation Genetic Diagnosis

    Product Type

    • Reagents and Consumables
    • Instruments
    • Software

    Technology

    • Next Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescent In-Situ Hybridization (FISH)
    • Other Technologies

    Application

    • Chromosomal Abnormalities
    • Aneuploidy Screening
    • X-linked Diseases
    • Embryo Testing
    • HLA Typing
    • Other Applications

    End-User

    • Hospitals
    • Fertility Centers
    • Diagnostic Centers
    • Research Centers and Academic Labs

    Drivers

    Increased Adoption of Assisted Reproductive Technologies (ART)

    Preimplantation Genetic Testing (PGT) market growth is being driven by increasing adoption of assisted reproductive technologies such as In Vitro Fertilization (IVF). With increasing numbers of individuals and couples turning to IVF for fertility solutions, PGT becomes an integral component in increasing its success rates; its ability to detect genetic abnormalities prior to implantation contributes significantly to better pregnancy outcomes.

    Growing Awareness of and Innovations in Genetic Testing Technologies

    Growing awareness among healthcare professionals and prospective parents about the benefits of genetic testing is driving its rise as an assessment tool. Technological advancements like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescent In-Situ Hybridization (FISH), have enhanced accuracy and efficiency of PGT; becoming reliable methods of assessing embryo health. Trend: PGT adoption as reliable evaluation method has seen rapid increase over time.

    Trend

    An Aneuploidy Screening Boom and Expanded PGT Applications

    One trend in the PGT market to watch out for is aneuploidy screening’s growing prevalence in IVF embryo quality evaluation, in line with increasing precision of fertility treatments. Furthermore, PGT applications are expanding beyond traditional genetic disorders to HLA typing for stem cell therapy to provide more holistic knowledge of embryonic health.

    Integrating Artificial Intelligence (AI) Into Genetic Analysis

    AI in genetic analysis represents a noteworthy trend. AI applications are now being employed to analyze vast datasets generated by genetic testing, making more precise and efficient identification of genetic abnormalities possible. Not only does this speed up analysis but it also aids with selecting healthy embryos for implantation more quickly. But this approach comes at a price there may be potential restrictions due to AI usage within genetic analysis itself.

    Restraint

    Ethical and Societal Concerns

    Ethical and societal concerns surrounding genetic testing and manipulation of embryos present a major challenge to widespread adoption of PGT technologies. Concerns such as selecting specific traits for designer babies and disposing nonviable embryos generate controversy and often resist widespread implementation of these technologies.

    Cost-Intensive Nature of PGT Procedures

    Preimplantation Genetic Testing procedures can be prohibitively expensive, making them inaccessible for some individuals or couples. PGT involves advanced technologies and expertise which may incur higher expenses; thus limiting adoption in regions with limited financial resources or inadequate insurance coverage.

    Opportunity

    Expanding Applications of Personalized Medicine

    One promising application of PGT lies in personalized medicine, with genetic testing technologies progressing and opening up opportunities for personalized treatments that match individual’s genetic makeup based on personalized healthcare interventions tailored specifically for them. PGT allows healthcare providers to identify genetic markers associated with diseases or conditions for more targeted care delivery.

    Concentration on Male Infertility and Sperm Genetic Testing

    There is an increasing opportunity in PGT’s landscape for male infertility and sperm genetic testing. While PGT traditionally focused on evaluating embryo genetic health, there has been increasing recognition of its value when applied to testing sperm quality and integrity – thus providing opportunities for creating advanced techniques to address male infertility comprehensively.

    Regional Analysis

    North America secured 36.4% market share and contributed USD 275.4 Million revenue to the global preimplantation genetics diagnosis (PGD) market in 2023, The rise of North America can be attributed to increasing healthcare expenditures coupled with an expanding population in this industry sector.

    Massachusetts, Columbia and New Jersey stand out with high rates of births that resulted from assisted reproductive technology; this underlines their involvement and success with PGD solutions.

    Preimplantation Genetic Testing Market Region

    Key Regions and Countries

    North America

    • The US
    • Canada
    • Mexico

    Western Europe

    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Portugal
    • Ireland
    • Austria
    • Switzerland
    • Benelux
    • Nordic
    • Rest of Western Europe

    Eastern Europe

    • Russia
    • Poland
    • The Czech Republic
    • Greece
    • Rest of Eastern Europe

    APAC

    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC

    Latin America

    • Brazil
    • Colombia
    • Chile
    • Argentina
    • Costa Rica
    • Rest of Latin America

    Middle East & Africa

    • Algeria
    • Egypt
    • Israel
    • Kuwait
    • Nigeria
    • Saudi Arabia
    • South Africa
    • Turkey
    • United Arab Emirates
    • Rest of MEA

    Key Player Analysis

    Industry players are taking steps to expand their presence across regional markets through various strategies, including the introduction of new products, acquisitions and collaborations. These endeavors should lead to improved product development capabilities, operational efficiencies and expanded market reach for those involved companies.

    Key Market Players

    • Quest Diagnostics Incorporated
    • Natera, Inc.
    • COOPER SURGICAL, INC.
    • Genea Pty Limited.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Bioarray S.L.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd

    Recent Developments

    • Quest Diagnostics Incorporated (May 2024): Quest Diagnostics announced the acquisition of a leading genetic testing lab, enhancing its capabilities in preimplantation genetic testing (PGT). The acquisition aims to expand their portfolio of reproductive health services and improve the accuracy and accessibility of genetic testing for IVF procedures.
    • Natera, Inc.(June 2024): Natera launched a new advanced PGT solution named Empower, designed to offer more precise and comprehensive genetic screening for IVF. Empower includes innovative technology for detecting genetic abnormalities, aiming to improve embryo selection and pregnancy outcomes.
    • COOPER SURGICAL, INC.(April 2024): Cooper Surgical introduced its latest PGT platform, Genesis Plus, featuring enhanced automation and higher throughput capabilities. The new product is expected to streamline lab workflows and provide more reliable results, supporting clinics in delivering better reproductive health services.
    • Genea Pty Limited (March 2024): Genea Pty Limited completed the merger with a prominent fertility clinic network, aiming to integrate advanced PGT services across its clinics. This merger is set to improve access to high-quality genetic testing and personalized fertility treatment plans for patients.
    • Invitae Corporation (February 2024): Invitae Corporation acquired a cutting-edge PGT technology firm, strengthening its position in the reproductive genetics market. The acquisition will enable Invitae to offer more sophisticated and accurate genetic testing solutions, supporting better outcomes in IVF treatments.

    Report Scope

    Report Features Description
    Market Value (2023) USD 756.6 Million
    Forecast Revenue (2033) USD 1648.6 Million
    CAGR (2024-2033) 8.1%
    Base Year for Estimation 2023
    Historic Period 2018-2022
    Forecast Period 2024-2033
    Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments
    Segments Covered By Procedure Type-(Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis) By Product Type-(Reagents and Consumables, Instruments, Software);By Technology-(Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Other Technologies);By Application-(Chromosomal Abnormalities, Aneuploidy Screening, X-linked Diseases, Embryo Testing, HLA Typing, Other Applications);By End-User-(Hospitals, Fertility Centers, Diagnostic Centers, Research Centers and Academic Labs)
    Regional Analysis North America-US, Canada, Mexico;Europe-Germany, UK, France, Italy, Russia, Spain, Rest of Europe;APAC-China, Japan, South Korea, India, Rest of Asia-Pacific;South America-Brazil, Argentina, Rest of South America;MEA-GCC, South Africa, Israel, Rest of MEA
    Competitive Landscape Quest Diagnostics Incorporated, Natera, Inc., COOPER SURGICAL, INC., Genea Pty Limited., Invitae Corporation, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Bioarray S.L., Illumina, Inc., F. Hoffmann-La Roche Ltd
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

    Frequently Asked Questions (FAQ)

    What is Preimplantation Genetic Testing (PGT)?

    PGT is a laboratory procedure performed during In Vitro Fertilization (IVF) to screen embryos for genetic abnormalities before implantation.

    How big is the Preimplantation Genetic Testing Market?

    The global Preimplantation Genetic Testing Market size was estimated at USD 756.6 Million in 2023 and is expected to reach USD 1648.6 Million in 2033.

    What is the Preimplantation Genetic Testing Market growth?

    The global Preimplantation Genetic Testing Market is expected to grow at a compound annual growth rate of 8.1%. From 2024 To 2033.

    Who are the key companies/players in the Preimplantation Genetic Testing Market?

    Some of the key players in the Preimplantation Genetic Testing Markets are Quest Diagnostics Incorporated, Natera, Inc., COOPER SURGICAL, INC., Genea Pty Limited., Invitae Corporation, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Bioarray S.L., Illumina, Inc., F. Hoffmann-La Roche Ltd

    Why is PGT Important in Assisted Reproductive Technologies (ART)?

    PGT enhances the success of ART by identifying genetically healthy embryos, reducing the risk of genetic disorders, and improving overall pregnancy outcomes.

    What Technologies are Commonly Used in PGT?

    Common technologies include Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescent In-Situ Hybridization (FISH).

    What Drives the Growth of the PGT Market?

    Increasing adoption of assisted reproductive technologies, growing awareness about genetic testing, and advancements in testing technologies contribute to the market's growth.

    Preimplantation Genetic Testing Market
    Preimplantation Genetic Testing Market
    Published date: July 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Quest Diagnostics Incorporated
    • Natera, Inc.
    • COOPER SURGICAL, INC.
    • Genea Pty Limited.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Company Profile
    • Bioarray S.L.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
  • settingsSettings

Related Reports

  • Influenza Diagnostics Market
  • Spectrometry Market
  • Colposcopy Market
  • Mesenchymal Stem Cells Market
  • Enteric Disease Testing Market
  • Preimplantation Genetic Testing Market
  • Autoimmune Disease Diagnostics Market
  • Live Cell Imaging Market
  • ADME-Toxicology Testing Market
  • Cell Dissociation Market

Our Clients

  • Our Clients
Inquiry Before Buying

Preimplantation Genetic Testing Market
  • 12405
  • July 2024
    • ★★★★★
      ★★★★★
    • (30)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.